Popular on eTradeWire

Similar on eTradeWire

Journey Medical Corp Announces New Journey with the Experts Video Featuring Naiem T. Issa, MD, PhD

eTradeWire News/10766686
Journey Medical Corporation
Dr. Issa discusses actinic cheilitis, a condition that may turn into squamous cell carcinoma

SCOTTSDALE, Ariz. - eTradeWire -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical") today released a new Journey with the Experts video featuring Naiem T. Issa, MD, PhD, a board-certified dermatologist and dermatologic surgeon with Forefront Dermatology in Vienna, Virginia. Dr. Issa sits down with Journey Medical to discuss actinic cheilitis, including what it is, why it occurs, and how those affected can seek treatment from their local dermatology practice.

According to the Cleveland Clinic, actinic cheilitis are precancerous lesions caused by long-term exposure to ultraviolet (UV) rays. To view the Journey with the Experts video featuring Dr. Issa, please visit https://vimeo.com/913735486/510cca855f.

About Journey with the Experts

Journey with the Experts is an educational initiative supported by Journey Medical Corporation, the medical dermatology company. The initiative is designed to educate the general public on common medical dermatology skin disorders and explain how these conditions can be treated at local dermatology practices.

The information, including, without limitation, topics, presentations, discussions, content, descriptions or any other material contained herein is for informational purposes only. None of the material herein is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified HCP with any questions you may have regarding a medical condition or treatment and before undertaking a new healthcare regimen. Never disregard professional medical advice or delay seeking it because of something you have heard, observed, or inferred herein. Any reliance is strictly prohibited.

About Journey Medical Corporation

Journey Medical is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology's most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (NASDAQ:FBIO). Journey Medical's common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission ("SEC"). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

More on eTradeWire News
About Naiem T. Issa, MD, PhD, FAAD

Dr. Issa is a dermatologist with Forefront Dermatology practicing in Vienna, Virginia, Assistant Professor at the University of Miami Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, Adjunct Professor at the George Washington University School of Medicine and Health Sciences, and Clinical Assistant Professor at the West Virginia School of Osteopathic Medicine.

Dr. Issa received his M.D. and Ph.D. from Georgetown University School of Medicine in Washington, D.C. He completed his internship in General Surgery at Washington Hospital Center. He then completed a post-doctoral research fellowship and Dermatology residency at the University of Miami/Jackson Memorial Hospital. His Ph.D. is in Tumor Biology from within the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center with a focus on computational methods for drug discovery. His work is particularly focused on repurposing of current FDA approved drugs for new dermatologic and cancer indications. Dr. Issa's research interests include drug discovery for hair loss, vascular malformations such as Sturge-Weber Syndrome and healing of chronic wounds. His major research accomplishments have been the repurposing of the anti-hookworm medication mebendazole as a kinase inhibitor and anti-angiogenic for various malignancies and the discovery of the first small molecule drug to directly inhibit the GNAQ protein implicated in Sturge-Weber Syndrome.

Dr. Issa is a nationally and internationally recognized lecturer and has authored over 30 peer-reviewed publications and two textbook chapters across various disciplines within dermatology and drug discovery. He has received research funding support from the Sturge-Weber Foundation, Dermatology Foundation, and the University of Miami Scientific Advisory Committee. He is also inventor of a patent on CBD nanoparticles combined with minoxidil for hair regrowth and a pending patent on a novel anesthetic combination for ambulatory skin surgeries designed to reduce the need for epinephrine. For additional information about Dr. Issa, please visit https://forefrontdermatology.com/provider/naiem-t-issa-md-phd/.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words "the Company", "we", "us" and "our" may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words "anticipate," "believe," "estimate," "may," "expect," "will," "could," "project," "intend," "potential" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third- party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could limit our products' commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful development and regulatory approval of the DFD-29 product candidate and any future product candidates that we may develop, in-license or acquire; clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties' cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2022, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

More on eTradeWire News
Media Contact
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500

Source: Journey Medical Corporation
Filed Under: Medical

Show All News | Report Violation